ModifiedUnitedHealthcarePolicy CS009ID.D

Spinal Fusion and Bone Healing Enhancement Products (for Idaho Only)

Defines medical necessity and investigational status of autograft, allograft, biologic, cell-based, and synthetic products used to enhance spinal fusion for members in Idaho, including Idaho Medicaid Plus.

Policy Summary

PayerUnitedHealthcare

PolicySpinal Fusion and Bone Healing Enhancement Products (for Idaho Only)

Policy CodePolicy CS009ID.D

Change TypeCoverage rationale updateddefinitions added

Effective DateMay 1, 2026

Next Review Date

Key ActionPrior authorization recommended for expandable interbody systems and certain ceramic-based or novel graft substitutes; verify benefit and document medical necessity.

SourceLink

POLICY UPDATE CHANGES

Added language to clarify Ceramic-Based Products (e.g., beta tricalcium phosphate (b-TCP), calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components, including Bone Marrow Aspirate (BMA), are unproven and not medically necessary.

Added definitions of Osseointegration, Osteoconduction, and Osteoinduction.

Updated definitions of Allograft, Autograft, and Bone Marrow Aspiration.

Updated Clinical Evidence, FDA, and References sections to reflect the most current information.

Idahogeographic application

1NMN material change

3new definitions added

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

InFUSEcovered for limited lumbar

limited/lowevidence concerns

Coverage Criteria and Medical Necessity

Medically necessary products and conditions

Covered when ALL of the following are met for specified products:

Autografts (including Bone Marrow Aspirate [BMA] used for bone grafting) are proven and medically necessary.

[[chunk 3]]

Demineralized Bone Matrix (DBM) is medically necessary when it does not include products listed as unproven and not medically necessary.

[[chunk 3]]

Allograft-based products are medically necessary except those specifically listed as unproven and not medically necessary.

[[chunk 3],[chunk 4]]

InFUSE (rhBMP-2) — lumbar: InFUSE Bone Graft (rhBMP-2) is medically necessary for lumbar spine only when ALL of the following are met: approach is anterior or oblique and used with an FDA‑approved interbody fusion device; patient is skeletally mature (≥18 years or radiographic epiphyseal closure) with degenerative disc disease; fusion involves L2–S1 (± spondylolisthesis ≤ grade 1); and single‑level fusion.

[[chunk 3],[chunk 28]]

InFUSE/MASTERGRAFT Posterolateral Revision Device System (or InFUSE BMP used with MASTERGRAFT) is medically necessary when used per FDA indications and ALL of the following: implanted via a posterolateral approach; symptomatic posterolateral lumbar pseudoarthrosis present; patient is skeletally mature (>21 years or radiographic epiphyseal closure); and autologous bone and/or bone marrow harvest is not feasible or not expected to promote fusion.

[[chunk 3]]

Unproven and not medically necessary products

Not medically necessary / unproven when ANY of the following product types are used for spinal fusion enhancement:

Cell-based allograft products: Allograft-based cell-containing products (e.g., mesenchymal stem cell [MSC]–containing) are unproven and not medically necessary due to insufficient evidence of efficacy and/or safety.

[[chunk 4],[chunk 18]]

Human amniotic tissue materials, including amniotic fluid stem cell substitutes, are unproven and not medically necessary.

[[chunk 4]]

Ceramic-based products, bioactive glass, and expandable interbody systems: Ceramic‑based products (e.g., beta tricalcium phosphate [b‑TCP], calcium phosphate, calcium sulfate), bioactive glass, and expandable interbody fusion systems are considered unproven and not medically necessary when used alone or combined with other grafts or graft components, including BMA, unless specific high‑quality evidence supports a given product/indication.

[[chunk 5],[chunk 36],[chunk 55]]

Coverage interpretation based on evidence strength

Summary coverage stance derived from evidence presented:

General evidence requirements: Coverage favors products supported by comparative, high‑quality evidence demonstrating efficacy and acceptable safety; products lacking such data are considered investigational or unsupported.evidence: comparative RCTs or high‑quality systematic reviews

Supported by multiple assessments noting limited evidence or absence of data (e.g., PrimaGen, OsteoAMP) [[18],[36]]

rhBMP‑2 considerations: rhBMP‑2 (Infuse) shows higher fusion rates in some studies but is associated with increased adverse events, particularly with cervical use; Infuse is FDA‑approved only for L2–S1 lumbar fusion, so off‑label cervical use requires strong justification and risk assessment.fusion benefit vs AE risk balance

ECRI and Hayes reviews report higher fusion but elevated AE rates and FDA warnings regarding off‑label cervical use [[28],[33]]

Products lacking evidence:

Evidence-based coverage considerations

Evidence summary: Multiple ceramic‑based and bioactive glass products have limited, heterogeneous evidence; some randomized intra‑patient PLF trials report noninferiority to autograft but are limited by small size and trial design, and overall evidence quality is insufficient to establish efficacy across products.

Summarized from clinical trials and ECRI assessments noting heterogeneity and limited data (e.g., Lehr et al., Stempels et al., MagnetOs) [[36],[55]]

Guideline/evidence summary

Guideline and evidence-based positions summarized (not an explicit policy decision in this excerpt):

AANS guideline positions: AANS (2014) supports DBM as a bone graft extender for 1‑ and 2‑level instrumented posterolateral fusions and considers b‑TCP/local autograft an option as a substitute for iliac crest bone autograft (AICB) for single‑level posterolateral fusion.

AANS guideline recommendations (Kaiser et al., 2014) [[chunk 61]]

Hydroxyapatite/calcium extenders: HA with local autograft/BMA can be used as a substitute for AICB or as a graft extender for instrumented posterolateral fusion; evidence is insufficient to recommend HA‑glass/BMA composites.

Guideline summary [[chunk 62]]

rhBMP‑2 guideline cautions: Society guidance notes rhBMP‑2 may be considered for select high‑risk indications (e.g., ALIF with appropriate cages, revisions, or high‑risk nonunion cases) but should not be used routinely for anterior/posterior cervical fusions, single‑level posterior/posterolateral fusions in healthy adults, or routine pediatric fusions.

NASS/AANS guidance and cautions summarized [[chunks 64,65,69]]

Not Medically Necessary: Ceramic-Based Products

Policy coverage stance updated to classify specific products as unproven and not medically necessary

Ceramic‑based products NMN: Ceramic‑Based Products (e.g., beta tricalcium phosphate [b‑TCP], calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components, including Bone Marrow Aspirate (BMA), are unproven and not medically necessary.

Added to Coverage Rationale; Policy change effective 05/01/2026 [[chunk 79]]

InFUSE (recombinant human bone morphogenetic protein-2, rhBMP-2) and the InFUSE/MASTERGRAFT Posterolateral Revision Device are covered only for the specific indications and conditions described in this policy. Use of InFUSE or InFUSE/MASTERGRAFT for indications not expressly listed in the medically necessary criteria is not covered. Providers should confirm that all coverage conditions for InFUSE (e.g., approach, anatomic levels, patient maturity, single-level fusion criteria) are met before requesting coverage or prior authorization for lumbar fusion cases using rhBMP-2. Documentation should explicitly reference the product and indication to support medical necessity and billing review.

Off‑label use of rhBMP‑2 (InFUSE) for cervical spine fusion has been associated with serious and potentially life‑threatening adverse events, including airway compression and neurologic compromise, and systematic reviews and evidence assessments report higher adverse event rates with rhBMP‑2 in cervical applications. Such off‑label cervical use requires careful risk assessment and strong supporting justification and may be excluded or require additional prior authorization documentation.

There is insufficient published clinical evidence to determine the safety and effectiveness of many ceramic‑based and related products. Evidence assessments report no or very limited clinical data for several specific products (for example, MagnetOs EasyPack Putty) and conclude that higher‑quality comparative trials with longer follow‑up are needed before these products can be considered proven for spinal fusion.

Expandable interbody fusion systems are considered unproven because prospective randomized controlled trials with sufficient sample size and longer‑term follow‑up are lacking. Systematic reviews and meta‑analyses of available studies show some radiographic differences (e.g., increased anterior disc height and segmental lordosis) but no clear clinical benefit over static cages in terms of pain or functional outcomes.

Ceramic‑based products (including beta tricalcium phosphate, calcium phosphate, and calcium sulfate) used alone or combined with other graft components are classified in this policy as unproven and not medically necessary (NMN). This operational coverage change clarifies that such ceramic materials, when used by themselves or with Bone Marrow Aspirate (BMA) or other grafts, are not supported by sufficient evidence for routine coverage.

Cell‑based allograft products (for example, mesenchymal stem cell–containing allografts) and human amniotic tissue materials, including amniotic fluid stem cell substitutes, are explicitly described as unproven and not medically necessary for enhancement of spinal fusion due to inadequate evidence of safety and efficacy.

The policy considers products that lack published clinical studies or have only small, low‑quality, or single‑center reports as investigational/unsupported. Examples cited in evidence assessments include PrimaGen Advanced Allograft and OsteoAMP, for which comparative data against autograft are insufficient; such products should be regarded as not meeting the evidence threshold for coverage until robust comparative data are available.

Specific products and classes identified with insufficient evidence include certain ceramic‑based grafts (e.g., MagnetOs EasyPack Putty), some bioactive glass formulations, and newer expandable or patient‑specific interbody implants (e.g., Aprevo). Evidence assessments note limited or no clinical studies for these products and rate the overall quality of evidence as very low or insufficient to determine comparative safety and effectiveness.

Multiple systematic reviews of expandable cages conclude that although expandable devices may improve some radiographic parameters (disc height, segmental lordosis), they do not show a consistent or meaningful improvement in clinical outcomes (pain, ODI) compared with static cages. The available evidence is predominantly retrospective and of low level, supporting the policy position that expandable systems are unproven for routine use.

Examples of ceramic‑based materials specifically noted in the policy as not medically necessary include beta tricalcium phosphate (b‑TCP), calcium phosphate, and calcium sulfate. The policy change effective 05/01/2026 explicitly classifies these materials, when used alone or combined with other graft components, as unproven and NMN.

Coding and Regulatory References

Applicable procedure codes (examples)CPT

0814T	Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral.
20930	Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure).
20931	Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure).
20939	Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine

FDA device submissions/approvals referencedmixed

OptiMesh (K014200)	510(k) for OptiMesh Expandable Interbody Fusion System.
DEN200010	De Novo classification for OptiMesh expanded indications (2020).
K210155	510(k) for Duo Expandable Interbody Fusion System (Feb 2021).
K172237	510(k) for Bicera Resorbable Bone Substitute (2018).
P000058	InFUSE Bone Graft PMA (supplements) / InFUSE approvals.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior authorization and coding references

Prior authorization requirements and coding references may apply for certain spinal grafting procedures and related services. Providers should follow applicable benefit and prior authorization rules and verify coverage with the member's plan prior to scheduling.

Check member benefit plan, federal/state/contractual requirements before applying this policy
Follow applicable prior authorization procedures per payer guidelines

Prior Authorization

Off‑label rhBMP‑2 risks and prior authorization

Infuse (rhBMP-2) use outside of approved lumbar indications (for example, cervical fusion) has been associated with life‑threatening adverse events such as airway or neurologic structure compression. Off-label use of rhBMP-2 may require prior authorization and additional documentation of risks and justification; providers should consider approved indications and alternative graft options (e.g., autograft) before proceeding.

Infuse (rhBMP-2) FDA approval limited to lumbar (L2–S1) interbody fusion in specified scenarios
Off-label cervical use linked to serious adverse events — document justification and risk/benefit discussion

Clinical Background

Autologous iliac crest bone graft (ICBG) remains the clinical reference standard for spinal fusion because it provides osteoconductive, osteoinductive, and osteogenic properties that promote bone healing. While ICBG has recognized donor‑site morbidity, comparative evidence frequently uses autograft as the benchmark when evaluating newer osteobiologics and synthetic substitutes.

Definitions

Allograft

DefinitionTransplant of an organ or tissue from one individual to another of the same species with a different genotype (also called allogeneic graft or homograft).

Typical sourcesDonated human bone used as morselized or structural allograft for spinal reconstruction (fresh-frozen or freeze-dried).

Regulatory noteWhen minimally manipulated and used as tissue for implantation, allografts are regulated as HCT/P by FDA; combination with other materials may be regulated as devices.

Autograft

DefinitionTissue grafted into a new position in the body of the same individual.

Clinical roleConsidered the gold‑standard autologous option (e.g., iliac crest bone graft) for spinal fusion due to osteogenic, osteoinductive and osteoconductive properties.

Policy Revision History

2026-05-01coverage_rationale_updateLatest

Added language classifying ceramic-based products (e.g., beta tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components, including bone marrow aspirate (BMA), as unproven and not medically necessary.

2026-05-01definitions_added

Added definitions for Osseointegration, Osteoconduction, and Osteoinduction to the policy.

2026-05-01

Policy Summary

PayerUnitedHealthcare

PolicySpinal Fusion and Bone Healing Enhancement Products (for Idaho Only)

Policy CodePolicy CS009ID.D

Change TypeCoverage rationale updateddefinitions added

Effective DateMay 1, 2026

Next Review Date

Key ActionPrior authorization recommended for expandable interbody systems and certain ceramic-based or novel graft substitutes; verify benefit and document medical necessity.

SourceLink

On This Page

Products with no published clinical studies or only small/single‑center studies (e.g., PrimaGen, OsteoAMP, MagnetOs EasyPack Putty, certain cell‑based or amniotic products) are considered experimental/investigational until adequate comparative evidence is available.

absence of peer‑reviewed comparative data

Documented lack of studies or limited, low‑quality studies across multiple product classes [[18],[36]]

Expandable device evidence: Systematic reviews report mixed radiographic benefits for expandable interbody devices (disc height, lordosis) but no clear clinical superiority over static cages; overall evidence quality is low and RCTs with longer follow‑up are lacking.

Systematic reviews and meta‑analyses (Lee et al., Johnson et al.) [[chunks 59,56,55]]

Bioactive glass evidence: Retrospective series of bioactive glass products report high radiographic fusion rates and symptom improvement but are limited by retrospective design, single‑center/surgeon cohorts, and risk of bias.

Case series data summarized (e.g., Westerland & Borden) [[chunk 54]]

Denial Risk

Denial risk for ceramic‑based products

Ceramic-based products (e.g., beta-tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or combined with other grafts/BMA are considered unproven and may be denied due to insufficient evidence of safety and efficacy. Use of these products can trigger claim denials or adverse coverage determinations when documentation does not support medical necessity.

Ceramic-based products alone or combined with other grafts/BMA are unproven and not medically necessary per policy update
Expect potential denial for use of ceramic-based substitutes without compelling, documented justification

Documentation Required

Medical records documentation requirements

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services. Documentation should be legible, maintained in the patient's medical record, and available upon request. Relevant documentation includes medical history, physical exam findings, diagnostic test results, imaging, operative notes, description of the product used, and rationale for choosing an advanced osteobiologic or off‑label therapy over standard options (e.g., autograft).

Include documentation of clinical indication, prior conservative treatments, and rationale for product selection
Document fusion assessment methods and patient‑reported outcomes when using osteobiologics (radiographic follow-up at 1 and 2 years when applicable)
When intra‑patient randomized trials or device‑specific studies support use, document product, study details, and justification

Prior Authorization

Consider autograft and prefer established grafts before novel substitutes

Consider autograft (ICBG) as the reference standard before selecting advanced osteobiologics or novel graft substitutes. Prefer established grafts (e.g., ICBG, DBM, allograft) prior to newer ceramic, bioactive glass, or expandable interbody systems unless there is documented justification (e.g., autograft not feasible).

Document why autograft is not feasible or expected to promote fusion when opting for alternatives
Prior authorization likely recommended for expandable interbody systems and novel grafts/devices with limited evidence

ConsiderationsAssociated with donor‑site morbidity when harvested (reason to consider alternatives).

Bone Marrow Aspiration (BMA)

DefinitionRemoval of a small amount of bone marrow in liquid form for examination or for use in grafting (Bone Marrow Aspiration, BMA).

UseBMA can be used as a source of osteogenic cells and is considered part of autograft strategies when used from the same patient.

DocumentationPolicy updates note BMA as a defined graft component and specify when combined products may be unproven (see coverage rationale).

Demineralized Bone Matrix (DBM)

DefinitionDemineralized Bone Matrix (DBM) is an allograft produced by dissolving the mineralized portion of bone and leaving the collagen matrix and retained growth factors.

PropertiesThe collagen matrix provides limited osteoconductive capacity while retained growth factors confer osteoinductive potential; DBM requires a carrier to serve as a potent osteoconductive scaffold.

Clinical roleUsed as a bone graft extender or supplement; coverage depends on product and evidence per policy.

InFUSE (rhBMP-2)

DefinitionInFUSE™ Bone Graft contains recombinant human bone morphogenetic protein‑2 (rhBMP‑2) and is a bone graft product intended to stimulate natural bone formation and remodeling.

IndicationsApproved for certain spine, dental, and trauma indications; Infuse (rhBMP‑2) is the only FDA‑approved spinal fusion product containing rhBMP‑2 and is approved for lumbosacral fusion L2–S1 when used per device labeling.

Safety noteEvidence assessments report higher fusion rates but also increased adverse events in some settings; off‑label cervical use has been associated with life‑threatening adverse events and requires strong justification.

Infuse (rhBMP-2)

Product descriptionInfuse is an absorbable collagen sponge coated with recombinant human bone morphogenetic protein‑2 (rhBMP‑2) used as a graft substitute alongside an interbody fusion cage.

Regulatory scopeIn the United States, Infuse is FDA‑approved only for lumbosacral spine fusion (L2 to S1).

Clinical implicationsIntended to promote vertebral fusion and avoid autograft harvest; studies show higher fusion but increased adverse event rates in some analyses, particularly in cervical use.

Allograft-based products

DefinitionAllograft‑based products are bone grafts derived from donated human bone that are processed to preserve bone‑forming cells or matrix components.

EvidenceClinical comparison data to autograft are often limited in quantity and quality; some products (e.g., PrimaGen, OsteoAMP) lack adequate comparative studies.

Regulatory/usage noteProducts vary by processing and cell content; coverage depends on evidence for each specific product per policy guidance.

Ceramic-based products

DefinitionCeramic‑based products are synthetic bone graft materials composed of calcium phosphates, hydroxyapatite, beta‑tricalcium phosphate (b‑TCP), calcium sulfate, and related formulations produced at high temperatures.

PropertiesThey provide osteoconductive scaffolds with variable composition, porosity, resorption profiles and clinical performance depending on manufacturing.

Coverage stancePolicy classifies many ceramic‑based products as unproven and not medically necessary when used alone or combined with other grafts/BMA unless specific evidence supports use.

Bioactive glass

DefinitionBioactive glass refers to silica‑based synthetic materials typically composed of SiO2, CaO, Na2O, and P2O5 that are claimed to form hydroxyl carbonated apatite and bond to bone.

Intended effectDesigned to promote faster HCA formation and bone bonding with higher osteoconductivity compared with some calcium phosphate ceramics.

EvidenceCurrent evidence is insufficient and very low quality to determine comparative safety and efficacy versus iliac crest bone graft (ICBG); RCTs are needed.

Allograft (structural)

DefinitionStructural allograft refers to cortical or corticocancellous bone (fresh‑frozen or freeze‑dried) used as a load‑bearing or spacemaking graft in spinal reconstruction.

UseMay be used with or without autograft for spinal reconstruction and is regulated as human tissue (HCT/P) when minimally manipulated.

Clinical noteChoice and processing of structural allograft affect mechanical properties and incorporation; coverage depends on product evidence and indication.

Expandable interbody fusion system

DefinitionAn expandable interbody fusion system is an interbody implant designed to be inserted in a collapsed configuration and then expanded in situ to restore disc height and alignment.

Device featuresSome devices have porous cavities for graft containment and designs intended to conform to anatomy and resist migration.

EvidenceSeveral expandable systems have received FDA 510(k) or De Novo clearances, but clinical evidence is limited and prospective RCTs with longer follow‑up are lacking.

Osseointegration

DefinitionOsseointegration is the stable anchorage of an implant achieved by direct bone‑to‑implant contact.

RelevanceA desired biologic outcome for implants and some graft materials aiming for long‑term fixation and load transfer.

Policy noteDefinition was added to the policy to clarify terminology used in evidence and device sections.

Osteoconduction

DefinitionOsteoconduction: the process by which bone grows on a scaffold or surface (bone grows on the surface).

Clinical roleCeramic and synthetic grafts commonly provide an osteoconductive scaffold to support host bone ingrowth.

Policy noteDefinition was added to the policy to standardize terminology across coverage and evidence summaries.

Osteoinduction

DefinitionOsteoinduction: the process by which osteogenesis is induced through recruitment and stimulation of immature cells to develop into preosteoblasts and osteoblasts.

Clinical roleProteins such as BMPs confer osteoinductive properties that can stimulate bone formation when combined with an osteoconductive scaffold.

Policy noteDefinition was added to the policy to clarify distinctions among graft material mechanisms (osteogenic, osteoinductive, osteoconductive).

Allograft (updated definition)

Updated definitionAllograft: Transplant of tissue from one individual to another of the same species with a different genotype (definition updated in policy).

ContextPolicy revision notes update and reaffirm allograft definitions and link to FDA HCT/P regulatory considerations.

ImplicationUpdated definition supports coverage distinctions between minimally manipulated allografts and processed combination products regulated as devices.

Autograft (updated definition)

Updated definitionAutograft: Tissue grafted into a new position in the body of the same individual (definition updated in policy).

Clinical emphasisPolicy reiterates autograft (e.g., iliac crest bone graft) as the reference standard in guideline summaries and coverage considerations.

ImplicationUpdated wording supports guidance to consider autograft before novel osteobiologics when clinically feasible.

Bone Marrow Aspiration (updated definition)

Updated definitionBone Marrow Aspiration: Removal of a small amount of bone marrow in liquid form for examination or for use in grafting (definition updated in policy).

Clinical roleBMA is recognized as a graft component and its combination with ceramic products is specifically addressed in the revised coverage rationale.

Policy implicationPolicy change clarifies that ceramic‑based products used alone or combined with BMA are unproven and not medically necessary unless evidence supports use.

Updated definitions for Allograft, Autograft, and Bone Marrow Aspiration.

2026-05-01supporting_information_updated

Updated Clinical Evidence, FDA, and References sections to reflect the most current information.